Therapeutic response of patients with adult Still's disease to biologic agents

Multicenter results in Japan

Rie Suematsu, Akihide Ohta, Emi Matsuura, Hiroki Takahashi, Takao Fujii, Takahiko Horiuchi, Seiji Minota, Yoshiaki Ishigatsubo, Toshiyuki Ota, Shuji Takei, Sachiko Soejima, Hisako Inoue, Syuichi Koarada, Yoshifumi Tada, Kohei Nagasawa

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective The efficacy of biologics in treating adult Still's disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed. Method Clinical data on 16 ASD patients who had been treated with at least 1 of the biological agents (total 24 occasions) were collected retrospectively. Results Infliximab was used in 9 cases, etanercept in 4, and tocilizumab in 11. Half of the patients that had been treated initially with infliximab or etanercept were changed to another biologics. Tocilizumab was effective in cases switched from another 2 drugs. Tocilizumab showed efficacy in treating both systemic and arthritic symptoms and showed apparent steroid-sparing effect and the highest continuation rate. Conclusion Tocilizumab may be a promising biologic agent in refractory ASD.

Original languageEnglish
Pages (from-to)712-719
Number of pages8
JournalModern Rheumatology
Volume22
Issue number5
DOIs
Publication statusPublished - Sep 1 2012

Fingerprint

Biological Factors
Japan
Biological Products
Therapeutics
Arthritis
Steroids
tocilizumab
Pharmaceutical Preparations
Etanercept
Infliximab

All Science Journal Classification (ASJC) codes

  • Rheumatology

Cite this

Therapeutic response of patients with adult Still's disease to biologic agents : Multicenter results in Japan. / Suematsu, Rie; Ohta, Akihide; Matsuura, Emi; Takahashi, Hiroki; Fujii, Takao; Horiuchi, Takahiko; Minota, Seiji; Ishigatsubo, Yoshiaki; Ota, Toshiyuki; Takei, Shuji; Soejima, Sachiko; Inoue, Hisako; Koarada, Syuichi; Tada, Yoshifumi; Nagasawa, Kohei.

In: Modern Rheumatology, Vol. 22, No. 5, 01.09.2012, p. 712-719.

Research output: Contribution to journalArticle

Suematsu, R, Ohta, A, Matsuura, E, Takahashi, H, Fujii, T, Horiuchi, T, Minota, S, Ishigatsubo, Y, Ota, T, Takei, S, Soejima, S, Inoue, H, Koarada, S, Tada, Y & Nagasawa, K 2012, 'Therapeutic response of patients with adult Still's disease to biologic agents: Multicenter results in Japan', Modern Rheumatology, vol. 22, no. 5, pp. 712-719. https://doi.org/10.1007/s10165-011-0569-6
Suematsu, Rie ; Ohta, Akihide ; Matsuura, Emi ; Takahashi, Hiroki ; Fujii, Takao ; Horiuchi, Takahiko ; Minota, Seiji ; Ishigatsubo, Yoshiaki ; Ota, Toshiyuki ; Takei, Shuji ; Soejima, Sachiko ; Inoue, Hisako ; Koarada, Syuichi ; Tada, Yoshifumi ; Nagasawa, Kohei. / Therapeutic response of patients with adult Still's disease to biologic agents : Multicenter results in Japan. In: Modern Rheumatology. 2012 ; Vol. 22, No. 5. pp. 712-719.
@article{ef139213cc504031bf84ab2fd60cbc5c,
title = "Therapeutic response of patients with adult Still's disease to biologic agents: Multicenter results in Japan",
abstract = "Objective The efficacy of biologics in treating adult Still's disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed. Method Clinical data on 16 ASD patients who had been treated with at least 1 of the biological agents (total 24 occasions) were collected retrospectively. Results Infliximab was used in 9 cases, etanercept in 4, and tocilizumab in 11. Half of the patients that had been treated initially with infliximab or etanercept were changed to another biologics. Tocilizumab was effective in cases switched from another 2 drugs. Tocilizumab showed efficacy in treating both systemic and arthritic symptoms and showed apparent steroid-sparing effect and the highest continuation rate. Conclusion Tocilizumab may be a promising biologic agent in refractory ASD.",
author = "Rie Suematsu and Akihide Ohta and Emi Matsuura and Hiroki Takahashi and Takao Fujii and Takahiko Horiuchi and Seiji Minota and Yoshiaki Ishigatsubo and Toshiyuki Ota and Shuji Takei and Sachiko Soejima and Hisako Inoue and Syuichi Koarada and Yoshifumi Tada and Kohei Nagasawa",
year = "2012",
month = "9",
day = "1",
doi = "10.1007/s10165-011-0569-6",
language = "English",
volume = "22",
pages = "712--719",
journal = "Modern Rheumatology",
issn = "1439-7595",
publisher = "Springer Japan",
number = "5",

}

TY - JOUR

T1 - Therapeutic response of patients with adult Still's disease to biologic agents

T2 - Multicenter results in Japan

AU - Suematsu, Rie

AU - Ohta, Akihide

AU - Matsuura, Emi

AU - Takahashi, Hiroki

AU - Fujii, Takao

AU - Horiuchi, Takahiko

AU - Minota, Seiji

AU - Ishigatsubo, Yoshiaki

AU - Ota, Toshiyuki

AU - Takei, Shuji

AU - Soejima, Sachiko

AU - Inoue, Hisako

AU - Koarada, Syuichi

AU - Tada, Yoshifumi

AU - Nagasawa, Kohei

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Objective The efficacy of biologics in treating adult Still's disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed. Method Clinical data on 16 ASD patients who had been treated with at least 1 of the biological agents (total 24 occasions) were collected retrospectively. Results Infliximab was used in 9 cases, etanercept in 4, and tocilizumab in 11. Half of the patients that had been treated initially with infliximab or etanercept were changed to another biologics. Tocilizumab was effective in cases switched from another 2 drugs. Tocilizumab showed efficacy in treating both systemic and arthritic symptoms and showed apparent steroid-sparing effect and the highest continuation rate. Conclusion Tocilizumab may be a promising biologic agent in refractory ASD.

AB - Objective The efficacy of biologics in treating adult Still's disease (ASD) is suggested, but the information is still lacking and the validation is insufficient. To determine the efficacy of several biologic agents in refractory ASD in Japan, a multicenter survey was performed. Method Clinical data on 16 ASD patients who had been treated with at least 1 of the biological agents (total 24 occasions) were collected retrospectively. Results Infliximab was used in 9 cases, etanercept in 4, and tocilizumab in 11. Half of the patients that had been treated initially with infliximab or etanercept were changed to another biologics. Tocilizumab was effective in cases switched from another 2 drugs. Tocilizumab showed efficacy in treating both systemic and arthritic symptoms and showed apparent steroid-sparing effect and the highest continuation rate. Conclusion Tocilizumab may be a promising biologic agent in refractory ASD.

UR - http://www.scopus.com/inward/record.url?scp=84870371697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870371697&partnerID=8YFLogxK

U2 - 10.1007/s10165-011-0569-6

DO - 10.1007/s10165-011-0569-6

M3 - Article

VL - 22

SP - 712

EP - 719

JO - Modern Rheumatology

JF - Modern Rheumatology

SN - 1439-7595

IS - 5

ER -